Tylenol Maker Kenvue Faces Mounting Crisis After Trump Blast

President Donald Trump, Tylenol Maker Kenvue Inc. For the company’s most well -known product, it has created a potentially existential crisis with three words: “Do not buy”.

Trump’s warnings about the unproven connection between the use of Tylenol during pregnancy during pregnancy in children revives the threshold of opening a lawsuit on the subject he is trying to put behind the company. In December, a Federal Court rejected cases claiming that there was a connection between active ingredient and developmental disorder in the treatment of overnight pain.

The US Food and Pharmaceutical Administration has initiated a label change process in products containing acetaminopen to say that the component is associated with higher risk of autism in children when taken by pregnant women. He also issued a letter that warns physicians throughout the country.

If FDA manages to force Kenvue to add the risks of autism to Tylenol’s label, consumers who have sued the company responsible for the autism of their children can use new warnings as evidence in court.

A renewed legal struggle, renewing its business, slowing down sales and making investors happy under temporary CEO Kirk Perry, the risk of removing a challenging Kenvue from the track. In addition, after seven people died in the 1980s, the Tylenol manufacturer has put the largest public relations crisis since seven people died.

“The lawyer of a senior plaintiff, who won a $ 4.7 billion decision against Kenvue’s former parent-Johnson & Johnson, said,“ Tylenol and the potential connections between autism for pregnancy and will take a new breath to this long-standing cases and will bring the issue to the forefront. The jury members gave money to 20 women with allegations that J & J undertakes cancer risks. This decision later fell to $ 2.1 billion and J & J paid $ 2.5 billion with interest.

Stacey Lee, a law professor at the University of Johns Hopkins, can serve as strong evidence before the juries, even if the new warning made by the FDA does not express a clear causal relationship between drugs and autism. In order to investigate a possible connection, research studies so far cannot determine the causality.

Kenvue spokesman, “FDA’s notification, ‘a causal relationship is not established’ says.

The World Health Organization said on Wednesday that there was no definite scientific evidence that connects the use of autism and acetaminophen during pregnancy despite widespread research.

Kenvue may try to sue the federal government, but law experts say that the company’s rates are weak that the company can earn such a lawsuit. The courts give a wide latitude to the FDA, especially when it comes to weigting health risks during pregnancy, Lee Lee said.

Elizabeth Burch, the law professor of law at Georgia University, said, “The real question is whether Kenvue’s claims will be an attempt to change the narrative, regardless of the legal validity,” Elizabeth Burch said. “Everyone can sue in this country. This case is a separate question for a judge to make a decision, whether it is very valuable or well -intentioned,” he added.

Kenvue’s shares changed very little on Wednesday morning. Kenvue’s shares have fallen 19% so far this year.

Mounting legal risks come after a lot of periods for Kenvue. Within two years after returning from Johnson & Johnson, consumer products company CEO Thibaut Mongon struggled to find a solid foundation under the Mongon and encouraged activist investors to increase the pressure of changes.

Earlier this year, Kenvue founded Jeffrey Smith, General Manager of Starkboard Value to eliminate the war of power of attorney with the Hedge Fund. Toms Capital Investment Management has collected a share in the company aiming to push Kenvue to cut off its portfolio. And in April, the Financial Times reported that the Hedge Fund was a share of the third point.

Kenvue announced a series of changes this summer to appease these investors, including the company looking for a permanent substitute, including setting up Perry as a temporary CEO. Kenvue also said that as well as others, the brand portfolio containing Neutrogena and Band-Aid has made a strategic review. Reuters, according to June, the company is considering the sale of some of the smaller skin care brands.

According to a person who is familiar with the sector that is not authorized to talk about the issue, the company is progressing with plans to facilitate brand management, including regional reorganizing leadership teams rather than a global model. He said these changes were planned for January.

Kenvue spokesman Melissa Witt said, “No decision was taken and we will not comment on rumors or speculation,” he said.

Economic ground, consumers permanent inflation, a slowed labor market and high interest rates under pressure caused by shopping did not help Kenvue’s situation. The company’s organic sales signed a contract for two successive quarters, a tendency to continue in the third quarter of analysts.

Kenvue, for the rest of the year, probably struggled with the execution problems that would probably continue last month full -year sales target.

According to Morningstar Analyst Keonhee Kim, Tylenol contributes to the medium-at-high single-digit percentage of sales and makes it the largest brand of Kenvue.

As a note to Citi analyst Filippo Falorni customers, as well as exposing the company to a number of legal risks, the government’s warning against Tylenol may damage the brand and reduce consumption. Falorni may scare a wider consumer set beyond waiting for mothers and push other pain reduction methods to use.

The wider scientific community warned that the government’s claims can create confusion for people who are particularly dangerous for pregnant mothers and their children.

This article was created from an automatic news agency feeding without changing the text.